Psychedelic News and Analysis Made Simple for Investors

Psychedelic Invest is a resource for those looking to invest in the burgeoning psychedelic industry.

Track the entire psychedelic market

Track the entire psychedelic market

We’ve developed the first all encompassing index to track the public psychedelic marketplace.

Explore the Index

Just Some of the Data we Cover

Latest News


Cybin Announces Date of Annual and Special Meeting of Shareholders

Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that its 2023 Annual and Special Meeting of Shareholders will be held virtually on Thursday, October 12, 2023 at 1:00 p.m. ET. The notice of annual and special…

Press Release Press

Transcend Therapeutics and Yale awarded U.S. Department of Defense grant to study methylone for PTSD

Company also announces that the IMPACT-1 clinical trial is underway with open-label results expected in the coming months Transcend Therapeutics, a biotechnology company developing rapid-acting treatments for neuropsychiatric diseases, announced receipt of a collaborative grant award with Yale University to support first-of-its-kind preclinical research on methylone – Transcend’s lead compound for the treatment of post-traumatic stress disorder…

Silo Pharma Press

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Pre-IND submission to FDA targeted for first quarter 2024 Silo partners with Kymanox for SPC-15 Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with…

Cybin Press

Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2 data for pivotal studies – – Breakthrough Therapy designation anticipated in late 2023, subject to FDA approval – – Previously announced acquisition of Small Pharma Inc. expected to close in…

Filament Health Press

Filament Health and Jaguar Health Joint Venture Magdalena Biosciences Completes Import of Coca Leaf From Peru

The import to Filament’s Metro Vancouver facility was conducted in collaboration with the Peruvian government and facilitated by Filament Health and Jaguar Health Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or “Filament Health”), a clinical-stage natural psychedelic drug development company, today announced that Magdalena Biosciences (“Magdalena”), a joint venture formed by Filament and Jaguar Health, Inc. (Nasdaq: JAGX) (“Jaguar…


Lucy Scientific Discovery: Navigating Growth and Diversification in the Psychedelic and Wellness Sectors

This has been a busy quarter for the psychedelic industry, particularly Lucy Scientific Discovery Inc. The company has announced three acquisitions in the past three months. These acquisitions create an interesting and unexpected pathway for the company. The NASDAQ-listed Lucy Scientific Discovery has greatly expanded its reach within the psychedelic, wellness, and cannabis industries this…


Interview with Red Light Holland CEO, Todd Shapiro

Psychedelic Invest’s Charley Rose sat down with the CEO of Red Light Holland, Todd Shapiro. During the interview, Charley does a deep dive into the company and its current positioning in the market. Red Light Holland is an expansive collection of mushroom brands. Todd Shapiro offers a fun and unique perspective on the global psychedelic…

Explore the Psychedelic Landscape

Learn more about the psychedelic companies changing the industry.